varespladib has been researched along with Infantile Respiratory Distress Syndrome in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Capoluongo, E; Conti, G; De Luca, D; Minucci, A; Trias, J; Tripodi, D; Zuppi, C | 1 |
| Capoluongo, ED; Cogo, PE; Conti, G; De Luca, D; Gentile, L; Giardina, B; Marzano, L; Minucci, A; Piastra, M; Vendittelli, F | 1 |
2 other study(ies) available for varespladib and Infantile Respiratory Distress Syndrome
| Article | Year |
|---|---|
Varespladib inhibits secretory phospholipase A2 in bronchoalveolar lavage of different types of neonatal lung injury.
Topics: Acetates; Albumins; Bronchoalveolar Lavage Fluid; Enzyme Inhibitors; Female; Gestational Age; Humans; Hyaline Membrane Disease; Indoles; Infant, Newborn; Italy; Keto Acids; Lung Injury; Male; Meconium Aspiration Syndrome; Pancreas; Phospholipases A2, Secretory; Respiratory Distress Syndrome, Newborn; Respiratory Tract Infections | 2012 |
Ex vivo effect of varespladib on secretory phospholipase A2 alveolar activity in infants with ARDS.
Topics: Acetates; Bronchoalveolar Lavage Fluid; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Indoles; Infant; Infant, Newborn; Keto Acids; Phospholipases A2, Secretory; Respiratory Distress Syndrome, Newborn | 2012 |